News
ONCO
2.575
-12.71%
-0.375
Weekly Report: what happened at ONCO last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at ONCO last week (1117-1121)?
Weekly Report · 11/24 10:19
Weekly Report: what happened at ONCO last week (1110-1114)?
Weekly Report · 11/17 10:19
Weekly Report: what happened at ONCO last week (1103-1107)?
Weekly Report · 11/10 10:17
Onconetix Files Prospectus For Resale Of 22.1M Shares Of Common Stock By Selling Stockholders
Benzinga · 11/04 22:44
Onconetix files to sell 22.07M shares of common stock for holders
TipRanks · 11/04 21:45
ONCONETIX INC - FILES PROSPECTUS FOR RESALE OF 22.1 MLN SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING
Reuters · 11/04 21:42
Weekly Report: what happened at ONCO last week (1027-1031)?
Weekly Report · 11/03 10:17
Onconetix Announces 2025 Annual Meeting Details
TipRanks · 10/29 16:48
Onconetix Inc. Announces Date for Upcoming Annual Stockholders Meeting
Reuters · 10/29 10:03
Weekly Report: what happened at ONCO last week (1020-1024)?
Weekly Report · 10/27 10:20
Weekly Report: what happened at ONCO last week (1013-1017)?
Weekly Report · 10/20 10:17
ONCONETIX INC - PROSPECTUS RELATES TO THE OFFER AND SALE OF UPTO 5,100,000 SHARES OF COMMON STOCK BY SELLING STOCKHOLDER - FILING
Reuters · 10/16 10:08
Weekly Report: what happened at ONCO last week (1006-1010)?
Weekly Report · 10/13 10:20
Weekly Report: what happened at ONCO last week (0929-1003)?
Weekly Report · 10/06 10:16
Onconetix Completes PIPE Financing Transaction
Barchart · 10/04 07:58
Onconetix Inc. Announces $6.25 Million Private Placement of Series E Preferred Stock and Warrants
Reuters · 10/03 12:16
Weekly Report: what happened at ONCO last week (0922-0926)?
Weekly Report · 09/29 10:17
Onconetix Completes $12.9M Private Placement
TipRanks · 09/26 13:15
More
Webull provides a variety of real-time ONCO stock news. You can receive the latest news about Onconetix through multiple platforms. This information may help you make smarter investment decisions.
About ONCO
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.